Sorrento Therapeutics' GAAP loss for 3 months of 2022 was $40.54 million, compared to a profit of $2.418 million in the previous year. Revenue increased by 29% to $18.385 million compared to $14.255 million a year earlier.

Scilex, a subsidiary of Sorrento Therapeutics, has entered into a merger agreement with SPAC Vickers Vantage Corp. I. In the escrow account of Vickers now has $140 million. Scilex shareholders will own 88% of the combined company, which will be called Scilex Holding Company, and its stock and warrants will trade on Nasdaq under the tickers SCLX and SCLXW. Th...

Sorrento Therapeutics' GAAP loss for 2021 was $429.138 million, up 36.5% from $314.41 million in the prior year. Revenue increased 32.3% to $52.904 million from $39.986 million a year earlier.

Sorrento Therapeutics has entered into an option agreement with Texas A&M University for an exclusive license to MPro inhibitors against coronavirus and its strains, including Delta. MPro inhibitors block the catalytic process to suppress viral replication in human host cells and prevent viral infection.